LITTLE FALLS, N.J., Oct. 19, 2012 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that it was named to the Forbes 2012 list of the "100 Best Small Companies in America." The Company was ranked number 61.
Cantel's President and CEO, Andrew Krakauer stated, "We are pleased to have been recognized for the success the Company has achieved both this year and over the past five years. I share this honor with our 1,200 hardworking and loyal employees. As a leader in the growing infection prevention and control market, the Company has performed well despite the difficult economic environment. We are optimistic that Cantel is positioned for sustained growth in the future. Our entire organization has a great sense of pride in providing the products, services and the guidance to mitigate infection risks, improve safety, and ultimately help save lives."
The Forbes rankings are based on one and five-year earnings growth, sales growth and return on equity. To qualify, companies must have sales between $5 million and $1 billion, and meet certain share price and other criteria. Forbes also considers a company's stock performance with its industry peers during the last year.
About Cantel Medical Corp. Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.